The patent office has officially issued a Notice of Allowance for Application US 18/547,664, marking a significant step forward in the fight against cancer. The technology, developed by Prakash Nallathamby and the research team, introduces a novel approach utilizing “Bispecific bridge nanoparticles.” Bridging the Gap in Cancer Treatment Current challenges in cancer therapy often revolve …
Tag Archive: biomimetic
May 24
MTEC Annual meeting in Baltimore MD (May 24, 2024)
Really useful information on working with the DoD’s medical enterprise. MTEC annual meeting in Baltimore, MD. Phage Mimicking antibacterial nanoparticles was a hit. New Partnering opportunity on the horizon. Exciting times ahead! #GOIRISH #MTEC #AMR #NEXTGEN #ANTIBIOTICS
May 07
Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024
Notre Dame senior Kevin Armknecht, affiliated with the Berthiaume Institute for Precision Health, has earned the Best Publication Imaging Award from ND’s Integrated Imaging Facility (NDIIF) for images he contributed to a recent Nanoscale Advances publication. Armknecht, who is majoring in pre-professional studies with minors in compassionate care in medicine and poverty studies, produced these …
Nov 16
Nallathamby Lab is one of 20 Participants Invited to Present Phage-Mimicking Antibacterial Nanoparticle Prototype at the Inaugural Joint Innovation Medical Symposium (JIMS) at Pope Army Airfield/Fort Bragg (Nov 16-17, 2022)
In recent combat theaters, despite advances in treating critical injuries leading to higher survival rates, there has been an increase in the number of infections linked to trauma, particularly those caused by bacteria resistant to multiple drugs 1,2. Research from the Trauma Infectious Disease Outcomes Study indicates that 27% of those evacuated with injuries develop …
May 14
Nallathamby Lab Presents Novel Antibacterial and Novel Chemotherapeutics Work at MRS 2022 Spring Meeting (May 8-13, 2022| Honolulu, Hawai’i)
Our research looks at the basic mechanism of drug resistance in bacteria or cancer cells and then we work on translational solutions to combat these problems. Our approach felt validated at this meeting where we networked with industry end-users as well as disease-on-a chip modeling academicians.
NIH Funding Opportunities
- Applicability of Transparency Act Subaward Reporting Requirements April 10, 2026Notice NOT-OD-26-066 from the NIH Guide for Grants and Contracts
- Notice of NINDS's Participation in PA-25-304: NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) April 9, 2026Notice NOT-NS-26-009 from the NIH Guide for Grants and Contracts
- Implementation of Changes for Basic Experimental Studies with Humans April 6, 2026Notice NOT-OD-26-067 from the NIH Guide for Grants and Contracts
Recent Comments